FDA Approves Celgene’s Otezla for PsA
The federal Food and Drug Administration has given its nod to Otezla (apremilast) for the treatment of adults with active psoriatic arthritis (PsA).
The federal Food and Drug Administration has given its nod to Otezla (apremilast) for the treatment of adults with active psoriatic arthritis (PsA).
The American Academy of Dermatology issued four strong evidence-based recommendations for the treatment of atopic dermatitis in adults in its 2025 focused update.